← Back to Search

Mineralocorticoid Receptor Antagonist

Finerenone for Chronic Kidney Disease (FIND-CKD Trial)

Phase 3
Waitlist Available
Research Sponsored by Bayer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Urine albumin/creatinine ratio (UACR) of ≥ 200 but ≤ 3500 mg/g and estimated glomerular filtration rate (eGFR) ≥ 25 but < 90 mL/min/1.73m^2 at screening
A clinical diagnosis of chronic kidney disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 50 months
Awards & highlights

FIND-CKD Trial Summary

This trial is being done to find out if the drug finerenone helps people with non-diabetic CKD.

Who is the study for?
Adults with non-diabetic chronic kidney disease (CKD) can join this trial. They must have a certain level of protein in their urine and a specific range of kidney function. Participants should be on stable doses of ACE inhibitors or ARBs for at least 4 weeks before the trial starts, without severe heart failure or diabetes, and not require immunosuppressive therapy for other kidney diseases.Check my eligibility
What is being tested?
The trial is testing if finerenone, a tablet taken once daily that blocks the hormone aldosterone, can slow down CKD progression compared to a placebo. The study will last up to about 50 months and involves regular health checks plus blood and urine tests while continuing current CKD medications.See study design
What are the potential side effects?
Possible side effects include changes in blood potassium levels which could affect heart rhythm, potential impacts on kidney function, and general risks like allergic reactions or gastrointestinal issues.

FIND-CKD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney tests show specific levels of protein in my urine and a certain rate of filtration.
Select...
I have been diagnosed with chronic kidney disease.

FIND-CKD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 50 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 50 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean rate of change as measured by the total slope of eGFR from baseline to Month-32.
Secondary outcome measures
Number of participants with Treatment-emergent adverse events (TEAEs), Treatment-emergent serious adverse events (TESAEs) and Adverse events of special interest (AESI)
Time to the composite of kidney failure or sustained eGFR decline of >= 57%
Time to the composite of kidney failure, sustained eGFR decline of >= 57%, heart failure hospitalization or Cardiovascular (CV) death
+1 more

Side effects data

From 2020 Phase 3 trial • 5734 Patients • NCT02540993
15%
Hyperkalaemia
9%
Nasopharyngitis
7%
Anaemia
7%
Hypertension
6%
Glomerular filtration rate decreased
6%
Back pain
6%
Oedema peripheral
6%
Upper respiratory tract infection
6%
Urinary tract infection
6%
Diarrhoea
5%
Arthralgia
5%
Dizziness
5%
Hypoglycaemia
5%
Constipation
4%
Bronchitis
2%
Acute kidney injury
2%
Pneumonia
1%
Sepsis
1%
Cellulitis
1%
Hyperglycaemia
1%
Diabetic nephropathy
1%
Cataract
100%
80%
60%
40%
20%
0%
Study treatment Arm
Finerenone
Placebo

FIND-CKD Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Finerenone (BAY94-8862)Experimental Treatment1 Intervention
Participants will receive finerenone.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Finerenone (BAY94-8862)
2013
Completed Phase 3
~15320

Find a Location

Who is running the clinical trial?

BayerLead Sponsor
2,237 Previous Clinical Trials
25,325,394 Total Patients Enrolled

Media Library

Finerenone (Mineralocorticoid Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT05047263 — Phase 3
Chronic Kidney Disease Research Study Groups: Finerenone (BAY94-8862), Placebo
Chronic Kidney Disease Clinical Trial 2023: Finerenone Highlights & Side Effects. Trial Name: NCT05047263 — Phase 3
Finerenone (Mineralocorticoid Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05047263 — Phase 3
Chronic Kidney Disease Patient Testimony for trial: Trial Name: NCT05047263 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To the best of your knowledge, is this research project without precedent?

"Finerenone (BAY94-8862), which was first studied in 2020, has had 2 clinical trials since then. The first one was sponsored by Bayer and occurred in 2020. After the initial Phase 3 drug approval 6000 people were enrolled. The second trial is currently ongoing and involves 448 cities across 39 countries."

Answered by AI

For what standard medical condition is Finerenone (BAY94-8862) prescribed?

"Finerenone (BAY94-8862) is a medication with multiple uses. It is commonly used to treat cardiovascular mortality, but can also be given to patients suffering from heart failure, type 2 diabetes mellitus, and myocardial infarction."

Answered by AI

Has Finerenone (BAY94-8862) received FDA sanctioning?

"Finerenone (BAY94-8862) has received a safety rating of 3. This is because Phase 3 trials, of which this medication is currently undergoing, have yielded some evidence of efficacy as well as multiple rounds data affirming its safety."

Answered by AI

Are there other instances where Finerenone (BAY94-8862) has been tested in a controlled setting?

"There are currently two Phase 3 trials underway for Finerenone (BAY94-8862), with a total of 1205 study sites worldwide."

Answered by AI

Who else is applying?

What state do they live in?
Missouri
North Carolina
Other
Texas
How old are they?
65+
18 - 65
What site did they apply to?
Renal Electrolyte and Hypertension Consultants
Emory University School of Medicine
St. Louis Heart & Vascular, PC
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
2

Why did patients apply to this trial?

I am on the pathway to a kidney transplant and would love to dodge it altogether if possible.
PatientReceived 1 prior treatment

What questions have other patients asked about this trial?

Will it kill me?
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
2021. "A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05047263.
All > Chronic Kidney Disease
~621 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top